Related references
Note: Only part of the references are listed.New hepatitis C therapies for special patient populations
Vincent Soriano et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
Jessica K. Dyson et al.
JOURNAL OF HEPATOLOGY (2016)
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Christoph Sarrazin
JOURNAL OF HEPATOLOGY (2016)
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection A Randomized Trial
Gregory T. Everson et al.
ANNALS OF INTERNAL MEDICINE (2015)
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
Stefan Zeuzem et al.
ANNALS OF INTERNAL MEDICINE (2015)
Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
Preethi Krishnan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
Christoph Sarrazin et al.
ANTIVIRAL RESEARCH (2015)
Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?
Andrew J. Muir et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects
Isabella Esposito et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Current and Evolving Treatments of Genotype 1 Hepatitis C Virus
Saleh Alqahtani et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2015)
Natural History of Hepatitis C
Shilpa Lingala et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2015)
Difficult-to-cure populations with chronic hepatitis c: Vanishing in the direct-acting antiviral era?
Norah Terrault
HEPATOLOGY (2015)
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
Tariq Ahmad et al.
HEPATOLOGY (2015)
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
David R. Nelson et al.
HEPATOLOGY (2015)
Hepatitis C virus drug resistance-associated substitutions: State of the art summary
Erik Lontok et al.
HEPATOLOGY (2015)
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis
Varun Saxena et al.
HEPATOLOGY (2015)
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
K. Rajender Reddy et al.
HEPATOLOGY (2015)
Continued Progress Against Hepatitis C Infection
Hari Conjeevaram
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C
Pablo Barreiro et al.
JOURNAL OF CLINICAL VIROLOGY (2015)
RESISTANCE ANALYSIS OF VIROLOGIC FAILURES IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS TREATED WITH GRAZOPREVIR/ELBASVIR plus /- RIBAVIRIN: THE C-WORTHY STUDY
S. Black et al.
JOURNAL OF HEPATOLOGY (2015)
Management of direct-acting antiviral agent failures
Maria Buti et al.
JOURNAL OF HEPATOLOGY (2015)
THE PREVALENCE AND THE EFFECT OF HCV NS5A RESISTANCE ASSOCIATED VARIANTS IN SUBJECTS WITH COMPENSATED CIRRHOSIS TREATED WITH LEDIPASVIR/SOFOSBUVIR plus /- RBV
C. Sarrazin et al.
JOURNAL OF HEPATOLOGY (2015)
LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A AND NS5B WITH PARITAPREVIR/R-, OMBITASVIR- AND DASABUVIR-BASED REGIMENS
P. Krishnan et al.
JOURNAL OF HEPATOLOGY (2015)
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
Oliver Lenz et al.
JOURNAL OF HEPATOLOGY (2015)
HCV targeting of patients with cirrhosis
Peter Ferenci et al.
JOURNAL OF HEPATOLOGY (2015)
EASL Recommendations on Treatment of Hepatitis C 2015
JOURNAL OF HEPATOLOGY (2015)
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy
C. Hedskog et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Estimates on HCV disease burden worldwide - filling the gaps
H. Wedemeyer et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
Anita Kohli et al.
LANCET (2015)
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
Marc Bourliere et al.
LANCET INFECTIOUS DISEASES (2015)
Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient
Richard A. Helmers et al.
MAYO CLINIC PROCEEDINGS (2015)
Avoiding treatment failures associated with HCV resistance
Jean-Michel Pawlotsky
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Bradyarrhythmias Associated with Sofosbuvir Treatment
Helene Fontaine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
D. L. Wyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
Julia Dietz et al.
PLOS ONE (2015)
The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment
Brian P. Lam et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2015)
Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis
Jonathan G. Stine et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
Clinical Evidence and Bioinformatics Characterization of Potential Hepatitis C Virus Resistance Pathways for Sofosbuvir
Eric F. Donaldson et al.
HEPATOLOGY (2015)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina et al.
HEPATOLOGY (2015)
Global Origin and Transmission of Hepatitis C Virus Nonstructural Protein 3 Q80K Polymorphism
Rosemary M. McCloskey et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance- Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors
V. C. Di Maio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Update on hepatitis C virus resistance to direct-acting antiviral agents
Eva Poveda et al.
ANTIVIRAL RESEARCH (2014)
Towards hepatitis C eradication from the HIV-infected population
Pablo Barreiro et al.
ANTIVIRAL RESEARCH (2014)
Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
Evguenia S. Svarovskaia et al.
CLINICAL INFECTIOUS DISEASES (2014)
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Ivan Gentile et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2014)
Evaluation of Liver Disease Progression in the German Hepatitis C Virus (1b)-Contaminated Anti-D Cohort at 35 Years After Infection
Manfred Wiese et al.
HEPATOLOGY (2014)
Antiretroviral Treatment of Adult HIV Infection 2014 Recommendations of the International Antiviral Society-USA Panel
Huldrych F. Guenthard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Global epidemiology and genotype distribution of the hepatitis C virus infection
Erin Gower et al.
JOURNAL OF HEPATOLOGY (2014)
Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation
Martina Gambato et al.
JOURNAL OF HEPATOLOGY (2014)
In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir
Xiao Tong et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns et al.
LANCET (2014)
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Eric Lawitz et al.
LANCET (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Therapy for Hepatitis C - The Costs of Success
Jay H. Hoofnagle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
James C. Sullivan et al.
CLINICAL INFECTIOUS DISEASES (2013)
Pharniacokinetics of new oral hepatitis C antiviral drugs
Eugenia Vispo et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
Khayriyyah Mohd Hanafiah et al.
HEPATOLOGY (2013)
Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy
Pablo Barreiro et al.
JOURNAL OF CLINICAL VIROLOGY (2013)
Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
Dennis Hernandez et al.
JOURNAL OF CLINICAL VIROLOGY (2013)
Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy
David L. Wyles
JOURNAL OF INFECTIOUS DISEASES (2013)
Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
E. B. Tapper et al.
JOURNAL OF VIRAL HEPATITIS (2013)
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
Doug J. Bartels et al.
JOURNAL OF VIROLOGY (2013)
VIRAL HEPATITIS Treating hepatitis C in injection drug users
Vincent Soriano et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
Ralf Bartenschlager et al.
NATURE REVIEWS MICROBIOLOGY (2013)
Antiviral activity and resistance of HCV NS5A replication complex inhibitors
Min Gao
CURRENT OPINION IN VIROLOGY (2013)
Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor
Zulema Plaza et al.
ANTIVIRAL THERAPY (2012)
Treatment failure with new hepatitis C drugs
Vincent Soriano et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
Fred Poordad et al.
GASTROENTEROLOGY (2012)
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Stephen S. Lim et al.
LANCET (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients
Ana Trevino et al.
ANTIVIRAL THERAPY (2011)
NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5
Sophie Vallet et al.
ANTIVIRAL THERAPY (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV
Jose Medrano et al.
CLINICAL INFECTIOUS DISEASES (2010)
Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients
Thomas Kuntzen et al.
HEPATOLOGY (2008)
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
Vincent Soriano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Treatment predictors of a sustained virologic response in hepatitis B and C
Annika Kau et al.
JOURNAL OF HEPATOLOGY (2008)
Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation
GW McCaughan et al.
LIVER TRANSPLANTATION (2003)
Share Paper
